Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4000 participants
OBSERVATIONAL
2010-08-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies
NCT01555346
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
Development of a Prenatal Test for Fetal Aneuploidy Detection
NCT01451671
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
NCT01052688
Automated Screen for Fetal Aneuploidy
NCT03635359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Positive for fetal aneuploidy
No interventions assigned to this group
Negative for fetal aneuploidy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a singleton pregnancy
* Subject is planning to undergo chorionic villus sampling (CVS) and/or amniocentesis with current pregnancy
* Subject is able to provide consent
Exclusion Criteria
* Subject (mother) has known aneuploidy
* Subject has active malignancy requiring major surgery or systemic chemotherapy or has a history of metastatic cancer.
* Subject has already undergone CVS or amniocentesis during current pregnancy prior to study enrollment.
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Sequencing Solutions
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ken Song, MD
Role: STUDY_DIRECTOR
Ariosa Diagnostics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Bay Perinatal Medical Associates
Oakland, California, United States
Prenatal Diagnosis of Northern California
Sacramento, California, United States
University of California - San Diego
San Diego, California, United States
University of California - San Francisco
San Francisco, California, United States
Atlanta Perinatal Consultants
Atlanta, Georgia, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TT001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.